Skip to main content

Advertisement

Table 2 Association between VEGF and eNOS polymorphisms and progression–free survival (PFS)

From: eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial

Polymorphisms CT + B CT
Median PFS (95% CI) HR (95% CI) P* Median PFS (95% CI) HR (95% CI) P*
VEGF −2578
 AA 9.3 (3.1–12.5) 1.18 (0.72–1.93)   9.1 (7.8–11.4) 1.27 (0.81–1.99)  
 CC/CA 10.4 (8.9–12.4) 1.00 0.515 9.0 (7.8–10.3) 1.00 0.304
VEGF −1498
 CC 9.1 (6.4–12.5) 1.30 (0.81–2.11)   9.1 (7.8–11.4) 1.21 (0.77–1.90)  
 TT/CT 10.7 (9.1–12.4) 1.00 0.277 9.0 (7.8–10.3) 1.00 0.406
VEGF −1154
 AA 11.5 (2.3–18.5) 1.09 (0.54–2.21)   9.1 (3.1–12.2) 1.74 (0.89–3.38)  
 GA/GG 10.3 (8.3–12.9) 1.00 0.808 9.6 (8.9–11.3) 1.00 0.105
VEGF −634
 GC 9.1 (7.5–11.3) 1.21 (0.81–1.82)   9.0 (7.0–10.3) 1.14 (0.77–1.68)  
 GG/CC 11.7 (9.1–12.9) 1.00 0.356 9.1 (8.0–11.3) 1.00 0.513
VEGF +936
 TT 7.8 (1.7–9.1) 3.63 (1.09–12.14)   28.0 (–) 0.34 (0.04–2.76)  
 CT/CC 10.2 (9.0–12.4) 1.00 0.036 9.1 (8.3–10.2) 1.00 0.311
eNOS +894
 GT 8.9 (6.8–10.2) 1.70 (1.12–2.60)   9.0 (7.4–9.6) 1.06 (0.73–1.54)  
 GG/TT 11.9 (9.6–14.1) 1.00 0.013 10.0 (8.3–11.4) 1.00 0.773
eNOS VNTR
 4bb 10.9 (9.1–12.9) 0.63 (0.41–0.96)   9.1 (8.3–10.3) 1.09 (0.69–1.74)  
 4ab/4aa 9.1 (6.2–11.3) 1.00 0.034 8.9 (6.1–11.6) 1.00 0.708
eNOS −786
 CC 12.7 (4.7–14.3) 0.90 (0.52–1.56)   8.9 (4.2–11.5) 1.17 (0.68–2.03)  
 CT/TT 9.6 (8.5–11.3) 1.00 0.709 9.1 (8.6–10.3) 1.00 0.572
  1. *Adjusted for CT (FOLFOX4/FOLFIRI), gender, age, KRAS status, tumor localization (rectum/colon).